Epigenome engineering: new technologies for precision medicine.

Area of Science:

• Epigenetics and molecular biology
• Gene editing technologies
• Cancer therapeutics

Background:

• Epigenetic marks regulate chromatin structure and gene expression.
• Approved epigenetic inhibitors have limitations in specificity and toxicity.
• CRISPR/dCas9/12a technology enables precise epigenome manipulation.

Purpose of the Study:

• To review state-of-the-art epigenome editing approaches for disease treatment.
• To highlight methods for engineering and delivering epigenetic effectors.
• To discuss the potential of locus-specific epigenome modification in personalized medicine.

Main Methods:

• Focus on CRISPR/dCas9/12a-based epigenome editing strategies.
• Review of biomolecular engineering for assembling and regulating epigenetic effectors.
• Discussion of delivery methods for therapeutic applications.

Main Results:

• Epigenome editing can reprogram diseased cells towards a normal-like state.
• CRISPR/dCas9/12a offers locus-specificity for targeted epigenetic modification.
• Engineering multiple effectors can enhance therapeutic longevity.

Conclusions:

• CRISPR/dCas9/12a epigenome editing is a promising frontier in precision medicine.
• Further development is needed to address targeting efficiency and intracellular delivery.
• This technology holds potential for treating neoplasms and other diseases.